Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Akorn launches generic antibiotic formulations
Buffalo Grove, IL—Now that patents have expired on two popular antibiotics, Akorn Inc. has launched generic versions of Alcon's Ciloxan and Ocuflox.
Buffalo Grove, IL-Now that patents have expired on two popular antibiotics, Akorn Inc. has launched generic versions of Alcon's Ciloxan and Ocuflox.
Ciprofloxacin ophthalmic solutions USP, 0.3%, and ofloxacin ophthalmic solution USP, 0.3%, were launched in the U.S. market in May. The company anticipates the combined market potential for both products to be more than $40 million.
The new products will be marketed through the company's existing distribution channels.
Related Videos
Related Content
